Hara Capital LLC Buys 3,024 Shares of Becton, Dickinson and Company $BDX

Hara Capital LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 902.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,359 shares of the medical instruments supplier’s stock after acquiring an additional 3,024 shares during the period. Hara Capital LLC’s holdings in Becton, Dickinson and Company were worth $629,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in BDX. Brighton Jones LLC increased its holdings in Becton, Dickinson and Company by 98.2% in the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. RiverGlades Family Offices LLC bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $344,000. Covea Finance grew its position in shares of Becton, Dickinson and Company by 10.7% during the 3rd quarter. Covea Finance now owns 78,847 shares of the medical instruments supplier’s stock worth $14,758,000 after buying an additional 7,610 shares during the period. Fort Washington Investment Advisors Inc. OH increased its stake in shares of Becton, Dickinson and Company by 2.0% in the 3rd quarter. Fort Washington Investment Advisors Inc. OH now owns 905,757 shares of the medical instruments supplier’s stock valued at $169,531,000 after acquiring an additional 17,844 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter valued at $983,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $205.89 on Friday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The stock has a market cap of $58.66 billion, a price-to-earnings ratio of 35.32, a PEG ratio of 2.28 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.64 and a current ratio of 1.11. The firm’s 50-day simple moving average is $197.22 and its 200 day simple moving average is $190.11.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The firm had revenue of $5.89 billion during the quarter, compared to analyst estimates of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The company’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period in the previous year, the company posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th were paid a dividend of $1.05 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. The ex-dividend date was Monday, December 8th. This represents a $4.20 annualized dividend and a yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 72.04%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on BDX shares. Wall Street Zen cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings reissued a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Stifel Nicolaus raised their target price on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Bank of America upped their price target on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Finally, Morgan Stanley increased their price target on Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $207.64.

Insiders Place Their Bets

In other news, Director Bertram L. Scott sold 217 shares of the company’s stock in a transaction on Friday, November 7th. The shares were sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,662 shares of company stock worth $535,246 over the last ninety days. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.